table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 prophylaxis (excluding children)
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
neutralizing antibody
bamlanivimab monotherapy BLAZE-2 US ...
casirivimab/imdevimab (Ronapreve) Cov-2069 ...
cilgavimab and tixagevimab (Evusheld) PROVENT

1 studies excluded by filtering options 0

5485 openSafely, 2020 0130selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons